Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lupin Ltd Capital/Financing Update 2024

Mar 22, 2024

61031_rns_2024-03-22_969cb6d4-aa88-4eeb-8f8e-7a85da4abd00.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [84 x 99] intentionally omitted <==

March 22, 2024

BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).

Dear Sir/Madam,

In compliance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we are pleased to inform you that as approved by the Board of Directors of Lupin Limited (‘the Company’), at its meeting held today i.e. March 22, 2024, the Company plans to carve out, its trade generics business in India, as a going concern, on a slump sale basis, to Lupin Life Sciences Limited (‘LLSL’), wholly owned subsidiary of the Company.

In this regard, the Company will enter into a Business Transfer Agreement with LLSL, particulars of which, are as under: -

a) the amount and percentage of the turnover or
revenue or income and net worth contributed
by such unit or division or undertaking or
subsidiary or associate company of the listed
entity during the last financial year;
The Company is proposing to transfer its
trade generics business in India along with
all related assets and liabilities including
but
not
limited
to
movable
assets,
products, employees, contracts (including
lease
deeds),
intellectual
property,
licenses, permits, consents, approvals,
transferable tax credits, trade receivables,
inventory, trade payables and insurance
policies (collectively ‘the undertaking’) to
Lupin Life Sciences Limited (‘LLSL’), a
wholly owned subsidiary of the Company.
FY23 revenues of the undertaking were
about ₹
2777
million.
The
revenues
represented 2.5% of the turnover of the
Company on a standalone basis, for the
year ended March 31, 2023.
Net worth of the undertaking as on March
31, 2023, was abouta721 million.
b) date on which the agreement for sale has been
entered into;
Business
Transfer
Agreement
(‘BTA’)
between the Company and LLSL is likely to
be entered into in Q1 FY25.
... 2.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [84 x 99] intentionally omitted <==

- 2 -
c) the
expected
date
of
completion
of
sale/disposal;
The slump sale of the undertaking on a
going concern basis shall be subject to
customary
satisfactory
completion
of
conditions precedent (including securing
requisite approvals) and in accordance
with the provisions of the BTA.
Completion of sale is expected to be
completed by end of business hours of
June 30, 2024 or such other date as may
be agreed upon by the Company and
LLSL.
d) consideration received from such sale/disposal; Consideration expected to be received is
₹1000 -₹1200 million, subject to any
movement in working capital and other
items in the intervening period up to
completion.
e) brief details of buyers and whether any of the
buyers belong to the promoter/promoter
group/group companies. If yes, details thereof;
LLSL, wholly owned subsidiary, the buyer,
was incorporated on July 17, 2023.
LLSL does not belong to the promoter/
promoter group/group companies.
f) whether the transaction would fall within
related party transactions? If yes, whether the
same is done at ‘arms-length’;
LLSL is a related party as per Section 2(76)
of the Companies Act, 2013 (‘Act’) and
Regulation 2(zb) of the Listing Regulations.
As the transaction is between holding
company and its wholly owned subsidiary,
there is no impact on a consolidated basis.
As per the provisions of Section 188 of the
Act and Regulation 23(5)(b) of the Listing
Regulations, provisions relating to related
party transactions are not applicable in
respect of transactions between holding
company and its wholly owned subsidiary
whose accounts are consolidated with the
holding company and placed before the
shareholders at the general meeting for
approval.
... 3.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [84 x 99] intentionally omitted <==

- 3 -

- 3 -
As
the
transaction
is
between
the
Company and LLSL, the entire economic
value
of
LLSL
will
remain
with
the
Company. Thus, arm’s length principle is
not relevant.
g) whether the sale, lease or disposal of the
undertaking
is
outside
Scheme
of
Arrangement? If yes, details of the same
including compliance with regulation 37A of
LODR Regulations;
Yes, the transaction is outside the Scheme
of Arrangement.
Regulation
37(A)(1)
of
the
Listing
Regulations is not applicable as the
transaction is not sale of whole or
substantially the whole of the undertaking
of the Company within the meaning of
Section 180(1)(a) of the Act.
Also, accounts of LLSL will be consolidated
with the Company.
h) i) names of entities forming part of the slump
sale, details in brief such as, size, turnover
etc.;
ii) whether the transaction would fall within
related party transactions? If yes, whether
the same is done at ‘arm’s length’;
The
Company,
Lupin
Ltd.
was
incorporated on March 1, 1983 (CIN:
L24100MH1983PLC029442)
and
has
its
registered office at 3rdFloor, Kalpataru
Inspire, Off Western Express Highway,
Santacruz (East), Mumbai - 400 055.
The standalone revenues of Lupin Ltd. in
FY23 werea112,588.3 million.
LLSL, was incorporated on July 17, 2023
and has its registered office at 3rdFloor,
Kalpataru Inspire, Off Western Express
Highway, Santacruz (East), Mumbai - 400
055.
As, LLSL was incorporated on July 17, 2023,
it did not have any revenues in FY23.
LLSL, wholly owned subsidiary of the
Company, is a related party as per Section
2(76) of the Companies Act, 2013 (‘Act’)
and
Regulation
2(zb)
of
the
Listing
Regulations.
As the transaction is between holding
company and its wholly owned subsidiary,
there is no impact on a consolidated basis.
... 4.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [84 x 99] intentionally omitted <==

- 4 -

- 4 -
As per the provisions of Section 188 of the
Act and Regulation 23(5)(b) of the Listing
Regulations, provisions relating to related
party transactions are not applicable in
respect of transactions between holding
company and its wholly owned subsidiary
whose accounts are consolidated with the
holding company and placed before the
shareholders at the general meeting for
approval.
As
the
transaction
is
between
the
Company and LLSL, the entire economic
value
of
LLSL
will
remain
with
the
Company. Thus, arm’s length principle is
not relevant.
(iii)area of business of the entities; The
Company
is
engaged
in
manufacturing, distribution, marketing and
sales of pharmaceuticals products and
active
pharmaceutical
ingredients/
intermediates
and
research
&
development.
LLSL shall be engaged, inter-alia in trade
generics business in India.
(iv)rationale for slump sale; The rationale for slump sale are:-
1) To achieve agility, better focus and
growth of trade generics business.
2) To increase business by investing in
new
launches
and
penetrating
underserved markets.
3) Trade generics are poised for higher
growth
given
the
need
for
accessibility,
availability
and
affordability of medicines. However,
there is specific focus required to
achieve this.

… 5.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

- 5 -

==> picture [84 x 99] intentionally omitted <==

(v)in case of cash consideration - amount or
otherwise share exchange ratio;
Cash consideration as specified in point
(d) above.
(vi)brief details of change in shareholding
pattern (if any) of listed entity.
There is no change in shareholding pattern
of the Company.

The Board meeting commenced at 6.30 p.m. (IST) and concluded at 7.35 p.m. (IST).

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan

Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2abcf74700f5375 b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb67a2ff09c4242 771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2024.03.22 19:40:41 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS -11973)

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com